Uterine Fibroids Treatment Market to Reach US$4.29 Billion by 2035, Driven by Rising Prevalence and Minimally Invasive Treatments

The global Uterine Fibroids Treatment Market reached USD 1.73 billion in 2025 and is expected to reach USD 4.29 billion by 2035, growing at a CAGR of 9.5% during the forecast period 2026-2035. The market is gaining momentum as the rising prevalence of uterine fibroids, increasing awareness of treatment options, improved diagnosis, and growing demand for minimally invasive procedures continue to drive treatment adoption. Advances in medical therapies and uterine-sparing treatment approaches are further supporting market expansion.

The competitive opportunity is increasingly focused on minimally invasive procedures, hormone-based therapies, targeted drug treatments, and uterine-preserving approaches. Growing preference for treatments that reduce symptoms, shorten recovery time, and preserve reproductive potential is encouraging innovation across the treatment landscape. The market is therefore shifting toward advanced pharmacological therapies, minimally invasive interventions, focused ultrasound technologies, and personalized treatment strategies, supporting sustained growth in the global uterine fibroids treatment market through 2035.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://www.datamintelligence.com/download-sample/uterine-fibroids-treatment-market?sai-v

Recent Developments

August 2026: North America continued advancing minimally invasive and non-surgical uterine fibroid treatments, with Medtronic, Boston Scientific, Stryker, and Insightec remaining key companies in treatment-device development.

July 2026: Asia-Pacific continued expanding access to fibroid diagnosis and treatment, particularly in China, Japan, and India, while research increasingly focused on AI-assisted pelvic imaging and real-time detection of uterine abnormalities.

June 2026: Europe continued adopting oral GnRH antagonist therapies, including relugolix, elagolix, and linzagolix, providing non-surgical options for women with symptomatic uterine fibroids.

May 2026: Pfizer and Myovant Sciences continued building clinical evidence around MYFEMBREE (relugolix combination therapy), supporting its role as an oral treatment option for fibroid-associated heavy menstrual bleeding.

April 2026: AbbVie, Takeda, and ObsEva remained prominent in the oral GnRH antagonist landscape, while treatment development increasingly focused on uterus-preserving therapies, minimally invasive procedures, and personalized treatment approaches.

Key Players
AbbVie Inc. | Pfizer Inc. | AstraZeneca | Kissei Pharmaceutical Co., Ltd. | Theramex | Others

Key Highlights
AbbVie Inc. - Holds an 18.0% share, supported by its strong women's health portfolio and leading position in uterine fibroid drug therapies. AbbVie is reported as the largest player in the uterine fibroid treatment drugs market.

Pfizer Inc. - Holds a 15.0% share, driven by its women's health portfolio, uterine fibroid treatment capabilities, and collaboration around Myfembree.

AstraZeneca - Holds a 10.8% share, supported by its pharmaceutical portfolio, women's health capabilities, and presence in the uterine fibroid treatment landscape.

Kissei Pharmaceutical Co., Ltd. - Holds a 8.6% share, strengthened by its GnRH antagonist portfolio and YSELTY (linzagolix), which is used for uterine fibroid treatment.

Theramex - Holds a 7.4% share, supported by its women's health portfolio and commercialization of Yselty (linzagolix) for uterine fibroids through its collaboration with ObsEva.

Others - Hold a combined 40.2% share, comprising additional pharmaceutical companies, specialty drug developers, medical-device companies, and emerging uterine fibroid treatment providers.

Get the Full Report Here: https://www.datamintelligence.com/buy-now-page?report=uterine-fibroids-treatment-market?sai-v

Market Drivers
Rising prevalence of uterine fibroids among women of reproductive age is increasing demand for effective medical and procedural treatment options.

Growing awareness of uterine fibroid symptoms, including heavy menstrual bleeding, pelvic pain, and reproductive complications, is supporting earlier diagnosis and treatment.

Increasing adoption of minimally invasive procedures, including uterine artery embolization, radiofrequency ablation, and focused ultrasound, due to shorter recovery times and reduced surgical burden.

Growing demand for pharmacological therapies that help manage heavy menstrual bleeding, pain, and fibroid-related symptoms while delaying or avoiding surgery.

Rising use of advanced imaging technologies, including ultrasound and MRI, is improving detection, diagnosis, and treatment planning for uterine fibroids.

Increasing focus on fertility-preserving treatment options among women seeking to maintain reproductive potential.

Growing healthcare expenditure and expansion of specialized gynecology services are improving access to uterine fibroid diagnosis and treatment.

Industry Developments
Development and adoption of novel medical therapies designed to reduce fibroid volume and control heavy menstrual bleeding with improved treatment outcomes.

Increasing clinical research into hormonal therapies, targeted drug delivery, and non-hormonal treatment approaches for uterine fibroids.

Strategic collaborations between pharmaceutical companies, biotechnology firms, medical device manufacturers, and healthcare providers to advance fibroid treatment solutions.

Growing adoption of minimally invasive and non-invasive procedures, including radiofrequency ablation, uterine artery embolization, and focused ultrasound.

Increasing integration of advanced imaging, image-guided procedures, and robotic technologies to improve treatment precision and patient outcomes.

Expansion of personalized treatment approaches based on fibroid size, location, symptoms, patient age, fertility goals, and treatment preferences.

Regional Insights
North America - 41% share: "Driven by high awareness of uterine fibroids, advanced gynecological care infrastructure, strong adoption of minimally invasive treatments, and significant investment in women's health."

Europe - 30% share: "Supported by established women's healthcare systems, increasing adoption of minimally invasive procedures, advanced diagnostic capabilities, and growing focus on fertility-preserving treatment."

Asia Pacific - 23% share: "Fueled by a large female population, improving women's healthcare infrastructure, rising awareness of uterine fibroids, and increasing access to advanced diagnostic and treatment technologies."

Latin America - 4% share: "Supported by improving gynecological healthcare services, increasing awareness of fibroid-related symptoms, and growing access to minimally invasive treatment options."

Middle East & Africa - 2% share: "Driven by improving women's healthcare infrastructure, increasing awareness and diagnosis of uterine fibroids, expanding specialized gynecology services, and growing access to advanced treatment options."

Speak to our analyst and get customization in the report as per your requirements: https://www.datamintelligence.com/customize/uterine-fibroids-treatment-market?sai-v

Key Segments
➥ By Type

Intramural Fibroids: Represents the dominant segment, driven by their high prevalence and increasing diagnosis of fibroids developing within the muscular wall of the uterus, often requiring medical or surgical management depending on symptoms.

Submucosal Fibroids: Represents a significant segment, supported by their association with heavy menstrual bleeding, reproductive complications, and increasing demand for effective treatment among symptomatic patients.

Subserosal Fibroids: Represents an important segment, fueled by the occurrence of pressure-related symptoms and increasing diagnosis of fibroids growing toward the outer surface of the uterus.

Pedunculated Fibroids: Represents a growing segment, supported by increasing recognition of this fibroid subtype and the availability of medical and surgical treatment options for symptomatic cases.

➥ By Treatment

Hormone Therapy: Represents a significant segment, driven by the use of hormonal approaches to manage symptoms such as heavy menstrual bleeding and regulate hormone-related fibroid growth.

Gonadotropin-Releasing Hormone (GnRH) Antagonists: Represents the dominant and rapidly growing segment, supported by their ability to reduce hormone stimulation of fibroids, improve heavy menstrual bleeding, and provide an effective medical treatment option.

GnRH Agonists: Represents an established segment, fueled by their ability to suppress estrogen and progesterone production, reduce fibroid size, and manage symptoms, particularly in selected patients before surgical treatment.

Progestins: Represents a significant segment, supported by their use in managing abnormal uterine bleeding and controlling symptoms associated with uterine fibroids.

Selective Progesterone Receptor Modulators (SPRMs): Represents an important segment, driven by their targeted effects on progesterone pathways and continued interest in medical approaches that can reduce fibroid-related symptoms.

Surgical Treatment: Represents the dominant and significant segment, supported by the need for definitive or procedural management in patients with large, symptomatic, rapidly growing, or treatment-resistant fibroids, including myomectomy and hysterectomy.

Explore Report Here: https://www.datamintelligence.com/research-report/uterine-fibroids-treatment-market

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.